WP
QTTB icon

Woodline Partners’s Q32 Bio QTTB Stock Holding History

Woodline Partners’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106,901
Closed -$4.77M – 1015
2024
Q3 		$4.77M Buy
+106,901
New +$3.93M 0.04% 392
2024
Q2 		– Sell
-15,584
Closed -$266K – 699
2024
Q1 		$266K Buy
+15,584
New +$215K ﹤0.01% 505
2022
Q1 		– Sell
-53,726
Closed -$3.52M – 836
2021
Q4 		$3.52M Buy
+53,726
New +$5.21M 0.05% 331

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Woodline Partners's QTTB Position: Q4 2024 in Review

Woodline Partners sold out of Q32 Bio (QTTB) in Q4 2024, closing a stake of 106,901 shares — an estimated $4.77M sold.

Woodline Partners first reported a position in QTTB in Q4 2021 and held it in 3 quarters. The position peaked at $4.77M in Q3 2024. 92 funds tracked by Wall St. Rank hold QTTB as of Q4 2024.

  • Woodline Partners reported no remaining Q32 Bio position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 106,901 Q32 Bio shares in Q4 2024, an estimated $4.77M.
  • Woodline Partners first reported a position in Q32 Bio in Q4 2021 and held it in 3 quarters.
  • Woodline Partners's Q32 Bio position peaked at $4.77M in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.